Form 4: Immuneering Director Receives Stock Option Grant

Director Thomas J. Schall was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Summary

• Director Thomas J. Schall received a grant of 33,350 stock options for Class A Common Stock.
• The options have an exercise price of $4.12 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Market volatility affecting the value of the underlying Class A Common Stock relative to the $4.12 exercise price.

Future Outlook

The options vest in equal monthly installments over one year, becoming fully vested by June 11, 2027, or the date of the 2027 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The one-year vesting period is relatively standard for director equity compensation in small-cap biotech firms.
• The grant size is consistent with typical annual equity retainers for board members in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options to commence on July 11, 2026.

Key Dates

Keywords

Immuneering, IMRX, Form 4, Insider Trading, Stock Options, Director Compensation